Clinicians frequently encounter patients presenting with acute myocardial infarction (AMI) who have already been taking aspirin or other antiplatelet agents. Understanding the impact of prior antiplatelet exposure is essential for risk stratification. Recently, a large-scale retrospective cohort study from Korea explored whether this prior exposure independently influences long-term clinical outcomes in East Asian populations. These patients often exhibit a distinct antithrombotic response profile, sometimes referred to as the "East Asian Paradox."

Researchers analyzed data from 21,304 patients across two nationwide Korean registries. They excluded individuals with complicating factors like atrial fibrillation or prior heart failure to isolate the effect of antiplatelet history. Initially, the data suggested that previous users had significantly higher rates of major adverse cardiac and cerebrovascular events (MACCE). However, these patients were also older and possessed more complex comorbidities. Consequently, the researchers used propensity score matching to ensure a fair comparison between groups.

Understanding the Impact of Prior Antiplatelet Exposure

The study found that prior antiplatelet exposure serves more as a marker of a high-risk clinical phenotype than an independent driver of poor outcomes. After matching for baseline differences, the adjusted hazard ratio for 3-year MACCE was 0.967, showing no significant difference between users and non-users. Furthermore, while all-cause death appeared slightly higher in the overall matched cohort, this association vanished in the more strictly selected population. These findings suggest that the baseline risk factors associated with why a patient was on antiplatelets carry more weight than the medication itself.

Additionally, platelet reactivity findings in the study supported the high-risk profile of prior users. However, these physiological markers did not translate into worse adjusted clinical outcomes. Therefore, clinicians should focus on individualized antithrombotic strategies tailored to a patient’s specific risk profile rather than just their medication history. This approach is particularly relevant in populations where bleeding and ischemic risks differ from Western cohorts.

Frequently Asked Questions

Does prior antiplatelet use increase the risk of death after AMI?

While unadjusted data may show higher mortality, this is largely due to the older age and higher comorbidity burden of these patients. When adjusted for these factors, prior antiplatelet use is not an independent predictor of long-term MACCE.

What is the "East Asian Paradox" mentioned in antiplatelet studies?

This refers to the observation that East Asian patients often have higher on-treatment platelet reactivity but a lower risk of ischemic events and a higher risk of bleeding compared to Western populations.

Should doctors change AMI treatment based on prior antiplatelet history?

The study suggests that treatment should be individualized. Prior exposure indicates a higher-risk patient, but the medication history itself does not necessitate a specific change in standard AMI management protocols without considering the full clinical context.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Oh S et al. Prior Antiplatelet Exposure and Clinical Outcomes Among Korean Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2026 Mar 20. doi: 10.1161/JAHA.125.045267. PMID: 41859899.

2. Kim HK et al. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy. Thromb Haemost. 2020;120(11):1607-1621.

3. Levine GN et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients. Nat Rev Cardiol. 2014;11(10):597-606.